Radiotherapy, Prostatectomy Confer Survival Advantages

Definitive treatment of localized prostate cancer seen as superior to conservative management

TUESDAY, Dec. 19 (HealthDay News) -- In men with localized prostate cancer, radiotherapy and radical prostatectomy provide significantly greater survival benefits than conservative management, according to a report published in the December issue of Urology.

Ashutosh Tewari, M.D., of the New York-Presbyterian Hospital-Weill Cornell Medical Center in New York City, and colleagues conducted a retrospective study of 3,159 men aged 75 and younger who were diagnosed with biopsy-confirmed, clinically localized prostate cancer between 1980 and 1997.

The researchers found that prostate cancer-specific survival at 15 years was better with radiotherapy and prostatectomy than conservative management (87 percent, 92 percent and 79 percent, respectively). This translated into median survival increases of 4.6 years for radiotherapy patients and 8.6 years for prostatectomy patients. They also found that the survival advantages persisted after adjusting for age, race, grade, coexisting illness, income status and year of diagnosis.

"Our study's strengths included its inclusion of three treatment modalities, a large database, long follow-up, representation of black patients, a single-institution setting, capture of comorbidity, adjustment for baseline confounders, and subgroup analysis," the authors write. "The findings therefore provide a useful addition to the present data."

Full Text (subscription or payment may be required)

Physician's Briefing